Together, these studies highlight the importance of ERβ in glioma biology, and suggest that ERβ agonists could serve as a viable therapeutic approach to target glioma stem cells and possibly reduce tumor recurrence and improve survival. This evidence concerns the gene ESR2 and neoplasm.